Literature DB >> 12467628

Development of an orexin-2 receptor selective agonist, [Ala(11), D-Leu(15)]orexin-B.

Shuichi Asahi1, Shin-Ichiro Egashira, Masao Matsuda, Hisashi Iwaasa, Akio Kanatani, Mitsuru Ohkubo, Masaki Ihara, Hajime Morishima.   

Abstract

Investigation of L-alanine and D-amino acid replacement of orexin-B revealed that three L-leucine residues at the positions of 11, 14, and 15 in orexin-B were important to show selectivity for the orexin-2 receptor (OX(2)) over the orexin-1 receptor (OX(1)). L-Alanine substitution at position 11 and D-leucine substitution at positions 14 and 15 maintained the potency of orexin-B to mobilize [Ca(2+)](i) in CHO cells expressing the OX(2), while their potency for the OX(1) was significantly reduced. In combined substitutions, we identified that [Ala(11), D-Leu(15)]orexin-B showed a 400-fold selectivity for the OX(2) (EC(50)=0.13nM) over OX(1) (EC(50)=52nM). [Ala(11), D-Leu(15)]orexin-B is a beneficial tool for addressing the functional roles of the OX(2).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12467628     DOI: 10.1016/s0960-894x(02)00851-x

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  29 in total

1.  Orexin receptor subtype activation and locomotor behaviour in the rat.

Authors:  W K Samson; S L Bagley; A V Ferguson; M M White
Journal:  Acta Physiol (Oxf)       Date:  2009-11-04       Impact factor: 6.311

Review 2.  Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA?

Authors:  Shaun Yon-Seng Khoo; Robyn Mary Brown
Journal:  CNS Drugs       Date:  2014-08       Impact factor: 5.749

3.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

4.  Stress induces analgesia via orexin 1 receptor-initiated endocannabinoid/CB1 signaling in the mouse periaqueductal gray.

Authors:  Hsin-Jung Lee; Lu-Yang Chang; Yu-Cheng Ho; Shu-Fang Teng; Ling-Ling Hwang; Ken Mackie; Lih-Chu Chiou
Journal:  Neuropharmacology       Date:  2016-02-18       Impact factor: 5.250

5.  Orexin regulates bone remodeling via a dominant positive central action and a subordinate negative peripheral action.

Authors:  Wei Wei; Toshiyuki Motoike; Jing Y Krzeszinski; Zixue Jin; Xian-Jin Xie; Paul C Dechow; Masashi Yanagisawa; Yihong Wan
Journal:  Cell Metab       Date:  2014-05-01       Impact factor: 27.287

Review 6.  Intranasal administration of orexin peptides: Mechanisms and therapeutic potential for age-related cognitive dysfunction.

Authors:  Coleman B Calva; Jim R Fadel
Journal:  Brain Res       Date:  2018-08-24       Impact factor: 3.252

7.  Crucial role of the orexin-B C-terminus in the induction of OX1 receptor-mediated apoptosis: analysis by alanine scanning, molecular modelling and site-directed mutagenesis.

Authors:  Pascal Nicole; Pierre Couvineau; Nadege Jamin; Thierry Voisin; Alain Couvineau
Journal:  Br J Pharmacol       Date:  2015-09-30       Impact factor: 8.739

8.  Orexins excite neurons of the rat cerebellar nucleus interpositus via orexin 2 receptors in vitro.

Authors:  Lei Yu; Xiao-Yang Zhang; Jun Zhang; Jing-Ning Zhu; Jian-Jun Wang
Journal:  Cerebellum       Date:  2010-03       Impact factor: 3.847

9.  Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX(2) receptor.

Authors:  P Malherbe; E Borroni; L Gobbi; H Knust; M Nettekoven; E Pinard; O Roche; M Rogers-Evans; J G Wettstein; J-L Moreau
Journal:  Br J Pharmacol       Date:  2009-04       Impact factor: 8.739

10.  Mechanisms underlying obesity resistance associated with high spontaneous physical activity.

Authors:  J A Teske; C J Billington; C M Kotz
Journal:  Neuroscience       Date:  2013-10-22       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.